Xianglai Xu

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Combination Therapy

Network Analysis

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Top Venues

Cancer medicine

Evolutionary bioinformatics online

This page only lists publications with an associated author ORCID identifier.

Publications

Jiajun Wang, Sihong Zhang, Ying Wang, Yanjun Zhu, Xianglai Xu, Jianming Guo
Effect of galectin-1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma. Cancer medicine 13 (7) (2024)
Jiajun Wang, Sihong Zhang, Ying Wang, Yanjun Zhu, Xianglai Xu, Jianming Guo
Effect of galectin-1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma. Cancer medicine 13 (7) (2024)
Xianglai Xu, Sihong Zhang, Ying Wang, Yanjun Zhu, Jiajun Wang, Jianming Guo
HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma. Cancer medicine (2023)
Xianglai Xu, Ying Wang, Zhaoyi Chen, Yanjun Zhu, Jiajun Wang, Jianming Guo
Unfavorable immunotherapy plus tyrosine kinase inhibition outcome of metastatic renal cell carcinoma after radical nephrectomy with increased ADAM9 expression. Immunogenetics 75 (2) (2022)
Xianglai Xu, Ying Wang, Zhaoyi Chen, Yanjun Zhu, Jiajun Wang, Jianming Guo
Unfavorable immunotherapy plus tyrosine kinase inhibition outcome of metastatic renal cell carcinoma after radical nephrectomy with increased ADAM9 expression. Immunogenetics (2022)
Xianglai Xu, Yelin Wang, Sihong Zhang, Yanjun Zhu, Jiajun Wang
Exploration of Prognostic Biomarkers of Muscle-Invasive Bladder Cancer (MIBC) by Bioinformatics. Evolutionary bioinformatics online 17 (2021)